NATCO Pharma Limited (IN:NATCOPHARM)
:NATCOPHARM
Want to see IN:NATCOPHARM full AI Analyst Report?
NATCOPHARM Stock Chart & Stats
₹893.35
-₹7.80(-0.59%)
At close: 4:00 PM EST
₹893.35
-₹7.80(-0.59%)
Day’s Range― - ―
52-Week Range₹789.30 - ₹1,226.10
Previous CloseN/A
Volume335.92K
Average Volume (3M)59.22K
Market Cap
₹206.99B
Enterprise Value₹211.90B
Total Cash (Recent Filing)₹40.77B
Total Debt (Recent Filing)₹2.61B
Price to Earnings (P/E)26.7
Beta0.99
Next Earnings
May 29, 2026EPS Estimate
15.76Next Dividend Ex-DateN/A
Dividend Yield0.57%
Share Statistics
EPS (TTM)85.91
Shares Outstanding179,109,860
10 Day Avg. Volume63,709
30 Day Avg. Volume59,218
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.90
Price to Sales (P/S)3.25
P/FCF Ratio10.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)39.96
Revenue Forecast (FY)₹32.11B
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low financial leverage and a high equity ratio provide durable financial flexibility. NATCO can fund R&D, regulatory filings and product launches, absorb pricing cycles, or pursue tuck-in M&A without forcing debt raises, supporting long-term strategic optionality.
Strong Cash GenerationRobust free cash flow growth and near-par conversion of earnings to cash indicate sustainable internal funding. Reliable cash generation supports reinvestment, commercialization of complex generics, and working capital for exports, reducing reliance on external capital over months to years.
High Margins & Revenue GrowthDouble-digit top-line growth combined with very high gross and EBITDA margins point to differentiated, higher-value products and efficient operations. Such structural profitability underpins durable cash flows and reinvestment capacity in complex generics and specialty formulations.
Bears Say
EPS ContractionNegative EPS growth signals underlying profitability volatility despite strong margins; it may reflect one-offs, pricing or product mix shifts that can persist. Prolonged EPS contraction can limit retained earnings, constrain reinvestment and raise investor scrutiny over execution.
Declining Gross Profit & Rising LiabilitiesA noted decline in gross profit paired with rising liabilities erodes margin cushions and balance-sheet resilience. If sustained, this trend could pressure operating margins and reduce flexibility to support launches or absorb regulatory and pricing headwinds over the medium term.
Capex Pressure RiskManagement caution on capital expenditures implies potential future spending needs to maintain or expand complex-manufacturing capacity. Higher or poorly-timed capex can reduce free cash flow and limit the company’s ability to fund commercialization or return capital, impacting durable cash profiles.
NATCO Pharma Limited News
NATCOPHARM FAQ
What was NATCO Pharma Limited’s price range in the past 12 months?
NATCO Pharma Limited lowest stock price was ₹789.30 and its highest was ₹1226.10 in the past 12 months.
What is NATCO Pharma Limited’s market cap?
NATCO Pharma Limited’s market cap is ₹206.99B.
When is NATCO Pharma Limited’s upcoming earnings report date?
NATCO Pharma Limited’s upcoming earnings report date is May 29, 2026 which is in 7 days.
How were NATCO Pharma Limited’s earnings last quarter?
NATCO Pharma Limited released its earnings results on Feb 12, 2026. The company reported ₹8.43 earnings per share for the quarter, beating the consensus estimate of ₹5.267 by ₹3.163.
Is NATCO Pharma Limited overvalued?
According to Wall Street analysts NATCO Pharma Limited’s price is currently Overvalued.
Does NATCO Pharma Limited pay dividends?
NATCO Pharma Limited pays a Quarterly dividend of ₹1.5 which represents an annual dividend yield of 0.57%. See more information on NATCO Pharma Limited dividends here
What is NATCO Pharma Limited’s EPS estimate?
NATCO Pharma Limited’s EPS estimate is 15.76.
How many shares outstanding does NATCO Pharma Limited have?
NATCO Pharma Limited has 179,109,860 shares outstanding.
What happened to NATCO Pharma Limited’s price movement after its last earnings report?
NATCO Pharma Limited reported an EPS of ₹8.43 in its last earnings report, beating expectations of ₹5.267. Following the earnings report the stock price went down -1.275%.
Which hedge fund is a major shareholder of NATCO Pharma Limited?
Currently, no hedge funds are holding shares in IN:NATCOPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NATCO Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Technical Analysis
Alembic Pharmaceuticals Limited
―
Granules India Limited
―
JB Chemicals & Pharmaceuticals Ltd.
―
Strides Pharma Science Ltd
―
Wockhardt Limited
―